Candel Therapeutics an off-the-shelf multimodal biological immunotherapy company empowering the patient's immune system to fight cancer.
Needham, MA
Joined January 2019
- Tweets671
- Following151
- Followers808
- Likes171
Last week, Candel joined LUNGevity’s Celebration of Hope and Progress in New York City.
Proud to support @lungevity.
Good to see @StermanDaniel, co-principal investigator of Candel’s phase 3 AURORA trial, and team from @NYULangone.
#LCAM #AnyoneWithLungs
It’s #Movember, a time to start conversations about men’s health.
We’re advancing an investigational viral immunotherapy for men with localized prostate cancer, and we’re grateful to the patients and families who make that work possible.
candeltx.com/
Candel CEO @PaulPeterTak will join a fireside chat at the @Stifel 2026 Healthcare Conference!
Details here: ir.candeltx.com/news-release…
#Stifel #Biotech
We’re sharing new data from three posters at @sitcancer #SITC26.
Aglatimagene showed immune activation in localized #ProstateCancer and #NSCLC, and linoserpaturev data show durable clinical outcomes in a subset of patients with recurrent #glioblastoma.
ir.candeltx.com/news-release…
We’re attending @UrologyUS LUGPA’s Annual Meeting.
Visit us at Booth 213 in the exhibit hall and at Booth 18 during the CME course to learn about our investigational aglatimagene program in localized #ProstateCancer.
We look forward to seeing you in Chicago #LUGPA2026!
We’re presenting a late-breaking abstract at @sitcancer!
@BaroneExpMed will present longitudinal immune profiling and biodistribution and shedding data from our phase 2 PrTK05 trial of aglatimagene in localized intermediate-risk #ProstateCancer.
ir.candeltx.com/news-release… #SITC26
November is #LungCancerAwarenessMonth.
1 in 19 people will be diagnosed with lung cancer in their lifetime.
Candel's phase 3 aglatimagene program has the potential to address unmet need in #NSCLC patients who progress after checkpoint inhibitors.
We support @lungevity.
It’s Brain Tumor Awareness Week.
Our linoserpaturev program targets recurrent high-grade glioma with next-generation replication-competent oncolytic HSV.
We’re advancing a treatment option for challenging brain cancers.
#BrainTumorAwareness
Our CEO @PaulPeterTak connected with Brad Loncar at @BiotechTV during the @HCWCO Annual Global Investment Conference about the path to BLA filing for aglatimagene in localized prostate cancer and our lung cancer program.
biotechtv.com/post/candel-th…
#BLA #ProstateCancer
Our Chief Scientific Officer @BaroneExpMed spoke with Zach Gobst on the Impactful Breakthroughs podcast about her journey to cancer immunotherapy, her "backpack theory" of continuous growth, and why patients must remain central to drug development.
share.transistor.fm/s/3723ad…
October is National Healthy Lung Month.
Our aglatimagene program targets unmet need in #NSCLC patients with progression despite checkpoint inhibitors. We recently initiated our global phase 3 AURORA trial to advance treatment options.
candeltx.com/
#HealthyLungMonth
#ICYMI We’ve appointed Martine Zimmermann, to our board of directors. She brings 30+ years of regulatory affairs and quality experience across multiple stages of drug development.
citybiz.co/article/901157/ca…
#Leadership
We’re presenting at @sitcancer’s Annual Meeting in November.
Two poster presentations on new data from our aglatimagene besadenovec program in non-small cell lung cancer and clinical findings from linoserpaturev in #glioblastoma.
ir.candeltx.com/news-release…
#SITC26 @baroneExpMed
Our CEO @PaulPeterTak will participate in a fireside chat at the 10th Global Prostate Cancer Summit taking place virtually October 6-8.
Learn more: admetech.org/annual-global-s…
#GPS2026 #ProstateCancer
New data at @ASTRO_org!
Digital pathology analysis demonstrates how aglatimagene activates immune response in localized #ProstateCancer.
The quantitative findings support the clinical benefit observed in our phase 3 trial.
ir.candeltx.com/news-release…
#ASTRO2026
For #ProstateCancerAwarenessMonth, our CEO @PaulPeterTak examines why diagnosis has transformed over two decades, but preventing recurrence in localized prostate cancer treated with curative intent remains an unmet challenge.
Read his @UrologyTimes op-ed urologytimes.com/view/after-…
On #WorldCancerResearchDay, we celebrate the research advancing cancer treatment.
Candel develops multimodal viral immunotherapies for prostate, lung, pancreatic, and brain cancers. Together with researchers and patients, we aim to build a better future.
candeltx.com/
We’re attending @BioCentury Grand Rounds in Amsterdam.
Our CEO @PaulPeterTak will moderate a panel, "Rethinking Autoimmunity," on Sept 25.
conferences.biocentury.com/g…
#Biotech #Innovation
On World Patient Safety Day, we highlight our commitment to safe multimodal viral immunotherapy development.
Patient safety guides every step of our clinical work and research.
#WorldPatientSafetyDay #PatientSafety
We’re presenting new aglatimagene data at @ASTRO_org 2026. Our Chief Scientific Officer, @baroneExpMed, is presenting quantitative digital pathology insights from our phase 3 trial in localized #ProstateCancer.
ir.candeltx.com/news-release…
#ASTRO2026 #Immunotherapy
